Thursday, November 12, 2026

Natural Gas Bullish Momentum: 3.26% Up Since The Last Session

ViaNews Editorial Team

January 15, 2021

Natural Gas Bullish Momentum: 3.26% Up Since The Last Session

Natural Gas is currently on bullish momentum. At 16:13 EST on Friday, 15 January, Natural Gas is at $2.75 and 3.26% up since the last session's close.

Natural Gas Range

Natural Gas is 3.457% up from its last session low of $2.66 and 2.686% up from its last session high of $2.68.

Natural Gas is 0.07% up from its last three sessions higher value of $2.75 and is 3.46% up from its last three sessions lower value of $2.66.

Natural Gas is 2.38% down from its last seven sessions higher value of $2.82 and is 5.88% up from its last seven sessions lower value of $2.60.

Natural Gas is 2.38% down from its last month's higher value of $2.82 and is 22.03% up from its last month's lower value of $2.26.

Volatility

Natural Gas's last day, last week, and last month's average volatility was a negative 2.33%, a negative 0.31%, and a negative 0.58%, respectively.

Natural Gas's last day, last week, and last month's high and low average amplitude percentage was 0.75%, 0.85%, and 1.76%, respectively.

Last news about Natural Gas

Shareholder alert: weisslaw LLP investigates corning natural gas holding corporation. According to Business Insider on Wednesday, 13 January, "WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Corning Natural Gas Holding Corporation ("Corning" or the "Company") (OTCQX: CNIG), a natural gas and electric service company, in connection with the proposed acquisition of the Company by an affiliate of Argo Infrastructure Partners, LP, an independent infrastructure investment firm. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com